Few studies were designed to study specific abnormalities related to anti-VEGF treatment and detected no systemic complications.[29,33,34] These negative results may be due to the fact that infants with ROP present more often with developmental disorders compared to other infants, causing difficulty in assessing systemic side effects of anti-VEGF treatment.[35] None of the babies showed any signs of systemic complications in our case series. This evidence concerns the gene VEGFA and retinopathy of prematurity.